Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Cinctive Capital Management LP

Key Points

• Cinctive Capital Management LP has increased its holdings in Alnylam Pharmaceuticals by 36.3%, bringing its total to $6.71 million with 24,862 shares.
• Several institutional investors, including Investment Management Corp of Ontario and Brevan Howard Capital Management LP, have also raised their positions in Alnylam Pharmaceuticals in the recent quarter.
• Analysts have set new price targets for Alnylam Pharmaceuticals, with Citigroup increasing its target from $527 to $583 and maintaining a "buy" rating.

Cinctive Capital Management LP grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 36.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,862 shares of the biopharmaceutical company's stock after purchasing an additional 6,622 shares during the period. Cinctive Capital Management LP's holdings in Alnylam Pharmaceuticals were worth $6,713,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Investment Management Corp of Ontario raised its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after acquiring an additional 40 shares in the last quarter. Brevan Howard Capital Management LP lifted its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 44 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Alnylam Pharmaceuticals by 10.3% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock worth $142,000 after buying an additional 49 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Alnylam Pharmaceuticals by 9.2% in the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp raised its position in shares of Alnylam Pharmaceuticals by 5.3% during the 1st quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock valued at $274,000 after buying an additional 51 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 5.2%

Shares of ALNY traded up $23.62 during midday trading on Tuesday, hitting $478.65. 1,719,201 shares of the company's stock traded hands, compared to its average volume of 962,484. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $480.18. The stock has a market capitalization of $62.74 billion, a price-to-earnings ratio of -193.46 and a beta of 0.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm's fifty day moving average is $390.05 and its 200-day moving average is $311.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same period last year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Jefferies Financial Group boosted their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research report on Monday, July 7th. BMO Capital Markets lifted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an "outperform" rating in a research note on Friday. Barclays increased their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Finally, UBS Group lifted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $417.38.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the transaction, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $632,764.92. Following the completion of the transaction, the executive vice president directly owned 22,719 shares of the company's stock, valued at $10,297,841.13. The trade was a 5.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,594 shares of company stock worth $25,551,456 in the last three months. Company insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.